1. Scrip
  2. >>R&D

Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail

Otsuka Obtains Global Rights To Two Drugs

 
• By Lisa Takagi

Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.

Sumitomo decided to prioritize other candidates than the four in the Otsuka deal amid financial challenges.
Sumitomo has decided to prioritize other R&D candidates over the four in its Otsuka alliance amid financial challenges • Source: Shutterstock

Amid recent financial challenges and R&D setbacks hitting Sumitomo Pharma Co., Ltd., the mid-sized Japanese firm has decided to prioritize its advanced candidates in oncology, regenerative medicine and the cell therapy area over its struggling assets in the antipsychotic space.

Sumitomo’s US subsidiary Sumitomo Pharma America, Inc. (SPMA) and Otsuka Pharmaceutical Co. Ltd. announced on 18 March a revision...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial